Search

Search Constraints

You searched for: Author/Creator Shimazaki, Tomoe

Search Results

1. Analysis of the optimal psoas muscle mass index cut‐off values, as measured by computed tomography, for the diagnosis of loss of skeletal muscle mass in Japanese people. Issue 6 (7th April 2020)

2. Anti‐adipogenic and antiviral effects of l‐carnitine on hepatitis C virus infection. Issue 5 (3rd October 2016)

3. Assessing the risk of hepatocellular carcinoma by combining liver stiffness and the controlled attenuation parameter. Issue 10 (10th July 2019)

4. Baseline angiopoietin‐2 and FGF19 levels predict treatment response in patients receiving multikinase inhibitors for hepatocellular carcinoma. Issue 5 (11th April 2020)

5. Computed tomography, not bioelectrical impedance analysis, is the proper method for evaluating changes in skeletal muscle mass in liver disease. Issue 2 (15th July 2020)

6. Early response and safety of lenvatinib for patients with advanced hepatocellular carcinoma in a real‐world setting. Issue 1 (10th June 2019)

7. Effects of nucleos(t)ide analogs on hepatitis B surface antigen reduction with interferon‐lambda 3 induction in chronic hepatitis B patients. Issue 7 (12th April 2022)

8. Effects of resistance‐associated variants in genotype 2 hepatitis C virus on viral replication and susceptibility to antihepatitis C virus drugs. Issue 11 (23rd July 2019)

9. Entecavir treatment of hepatitis B virus‐infected patients with severe renal impairment and those on hemodialysis. Issue 11 (25th July 2019)

10. High serum angiopoietin‐2 level predicts non‐regression of liver stiffness measurement‐based liver fibrosis stage after direct‐acting antiviral therapy for hepatitis C. Issue 6 (18th February 2020)